1. Home
  2. ICUI vs IPAR Comparison

ICUI vs IPAR Comparison

Compare ICUI & IPAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • IPAR
  • Stock Information
  • Founded
  • ICUI 1984
  • IPAR 1982
  • Country
  • ICUI United States
  • IPAR United States
  • Employees
  • ICUI N/A
  • IPAR N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • IPAR Package Goods/Cosmetics
  • Sector
  • ICUI Health Care
  • IPAR Consumer Discretionary
  • Exchange
  • ICUI Nasdaq
  • IPAR Nasdaq
  • Market Cap
  • ICUI 3.3B
  • IPAR 3.9B
  • IPO Year
  • ICUI 1992
  • IPAR 1988
  • Fundamental
  • Price
  • ICUI $119.25
  • IPAR $95.19
  • Analyst Decision
  • ICUI Buy
  • IPAR Strong Buy
  • Analyst Count
  • ICUI 6
  • IPAR 4
  • Target Price
  • ICUI $186.60
  • IPAR $162.00
  • AVG Volume (30 Days)
  • ICUI 285.2K
  • IPAR 305.0K
  • Earning Date
  • ICUI 11-11-2025
  • IPAR 11-05-2025
  • Dividend Yield
  • ICUI N/A
  • IPAR 3.41%
  • EPS Growth
  • ICUI N/A
  • IPAR 14.29
  • EPS
  • ICUI N/A
  • IPAR 5.02
  • Revenue
  • ICUI $2,372,504,000.00
  • IPAR $1,458,888,000.00
  • Revenue This Year
  • ICUI N/A
  • IPAR $4.18
  • Revenue Next Year
  • ICUI N/A
  • IPAR $5.29
  • P/E Ratio
  • ICUI N/A
  • IPAR $18.69
  • Revenue Growth
  • ICUI 2.96
  • IPAR 7.04
  • 52 Week Low
  • ICUI $107.00
  • IPAR $92.46
  • 52 Week High
  • ICUI $196.26
  • IPAR $148.15
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 42.14
  • IPAR 24.71
  • Support Level
  • ICUI $117.69
  • IPAR $93.07
  • Resistance Level
  • ICUI $125.00
  • IPAR $95.20
  • Average True Range (ATR)
  • ICUI 4.04
  • IPAR 2.09
  • MACD
  • ICUI -0.69
  • IPAR -0.24
  • Stochastic Oscillator
  • ICUI 23.20
  • IPAR 11.84

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About IPAR Inter Parfums Inc.

Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.

Share on Social Networks: